clinical trial · NCT05765344
Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function
Gilead Sciences·phase1·completed·n = 74
Hepatic ImpairmentHealthyBulevirtideBulevirtide
brief summary
The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal and impaired hepatic (liver) function.
started
Mar 15, 2023
primary completion
Jan 10, 2025
completion
Jan 13, 2025
last updated
Jan 26, 2026
official title
A Phase 1, Open-label, Parallel-group, Multiple-dose Study to Evaluate the Pharmacokinetics of Bulevirtide in Participants With Normal and Impaired Hepatic Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol